Bariatric surgery as a treatment of polycystic ovary syndrome: a systematic review and meta-analysis
Abstract
Background: Polycystic ovary syndrome (PCOS) is the most common endocrine disorder among females of reproductive age, and the majority are obese/overweight. PCOS management, including lifestyle and drugs, is limited by unsustainability and side effects. Bariatric surgery (BS) is promising in addressing hyperandrogenism and pregnancy outcomes. We aimed to assess the impact of bariatric surgery on PCOS components.
Methods: We systematically searched PubMed/MEDLINE, Google Scholar, Cochrane Library, and Web of Science during July and August 2025, articles from inception up to August 2025 were included. The keywords used were BS, sleeve gastrectomy, gastric bypass, gastric banding, menstrual irregularities, free testosterone, total testosterone, hirsutism, SHBG, lutenizing hormone, antimullarian hormone (AMH), follicle-stimulating hormone, and pre-term deliveries. 648 articles were eligible, 35 full texts were reviewed, and 27 were included in the final meta-analysis.
Results: Bariatric surgery reduced menstrual irregularities and hirsutism, with odds ratios of 27.68, 95% CI, 9.83-78.00, and 6.61, 95% CI, 0.97-47.07, respectively. In addition, total testosterone, free testosterone, AMH, and LH were reduced, SD, -19.95, 95% CI, -28.53-11.38, SD, 2.40, 95% CI, 1.30.53-3.51, SD, 1.66, 95% CI, 0.17-3.14, and SD, 2.21, 95% CI, 1.73-2.69 respectively, while SHBG were increased. No effects were observed regarding FSH, birth weight, gestational age, and pre-term delivery.
Conclusion: BS…
How strong is the evidence?
Evidence Hub reads this as a meta-analysis, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid.
Read the paper
Related studies
- Increased expression of circulating miRNA-93 in women with polycystic ovary syndrome may represent a novel, non-invasive biomarker for diagnosis
- Identification of key genes associated with polycystic ovary syndrome (PCOS) and ovarian cancer using an integrated bioinformatics analysis
- Identification of key pathways and genes in polycystic ovary syndrome via integrated bioinformatics analysis and prediction of small therapeutic molecules
- Regulation of Androgen Receptor Expression Alters AMPK Phosphorylation in the Endometrium: In Vivo and In Vitro Studies in Women with Polycystic Ovary Syndrome
- Effect of oral administration of low-dose follicle stimulating hormone on hyperandrogenized mice as a model of polycystic ovary syndrome
- Systems pharmacology to investigate the interaction of berberine and other drugs in treating polycystic ovary syndrome
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.